Overview

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

Status:
NOT_YET_RECRUITING

Trial end date:
2032-05-01

Target enrollment:

Participant gender:

Summary

This is a multi-center, non-randomized, open-label, dosimetry and dose-escalation, cohort-expansion study of LNTH-2403 administered to subjects with relapsed / refractory (R/R) osteosarcoma. This study consists of 2 phases: (1) a dosimetry and dose escalation phase; and (2) a cohort expansion phase.

Phase:

PHASE1

Details

Lead Sponsor:

Lantheus Medical Imaging

Treatments:

Clinical Trials, Phase II as Topic